American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
. APA, 2013.
Alderfer, BS, Allen, MH. Treatment of agitation in bipolar disorder across the life cycle. J Clin Psychiatry
2003; 64 (suppl 4): 3–9.
Hankin, CS, Bronstone, A, Koran, LM. Agitation in the inpatient psychiatric setting: a review of clinical presentation, burden, and treatment. J Psychiatr Pract
2011; 17: 170–85.
Marder, SR. A review of agitation in mental illness: treatment guidelines and current therapies. J Clin Psychiatry
2006; 67 (suppl 10): 13–21.
Nordstrom, K, Allen, MH. Alternative delivery systems for agents to treat acute agitation: progress to date. Drugs
2013; 73: 1783–92.
Bourdinaud, V, Pochard, F. Survey of management methods for patients in a state of agitation at admission and emergency departments in France [in French]. Encephale
2003; 29: 89–98.
Adasuve [prescribing information]. Alexza Pharmaceuticals, 2013.
Lesem, MD, Tran-Johnson, TK, Riesenberg, RA, Feifel, D, Allen, MH, Fishman, R, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry
2011; 198: 51–8.
Kwentus, J, Riesenberg, RA, Marandi, M, Manning, RA, Allen, MH, Fishman, RS, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord
2012; 14: 31–40.
Citrome, L. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder. Int J Clin Pract
2012; 66: 318–25.
Montoya, A, Valladares, A, Lizan, L, San, L, Escobar, R, Paz, S. Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcomes
2011; 9: 18.
Emsley, R, Rabinowitz, J, Torreman, M. The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophr Res
2003; 61: 47–57.
Leucht, S, Kane, JM, Kissling, W, Hamann, J, Etschel, E, Engel, RR. What does the PANSS mean?
2005; 79: 231–8.
Pratts, M, Citrome, L, Grant, W, Leso, L, Opler, LA. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand
2014; 130: 61–8.
Citrome, L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry
2007; 68: 1876–85.
Spyker, DA, Munzar, P, Cassella, JV. Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol
2010; 50: 169–79.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). APA, 2000.
Kay, SR, Fiszbein, A, Opler, LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull
1987; 13: 261–76.
Kay, SR. Significance of the positive-negative distinction in schizophrenia. Schizophr Bull
1990; 16: 635–52.
Dinh, K, Myers, DJ, Noymer, PD, Cassella, JV. In vitro aerosol characterisation of Staccato® Loxapine. Int J Pharm
2011; 403: 101–8.